OmniAb, Inc.

OmniAb, Inc. (OABI) is a biotechnology company specializing in antibody discovery technology that completed its business combination with Avista Public Acquisition Corp. II, sponsored by Avista Capital Partners, in October 2022. The blank-check vehicle conducted its initial public offering in 2021 under a life sciences sector focus. On February 7, 2023, OmniAb filed an amended registration statement (S-1/A) with the SEC, a post-merger step to register securities for resale. Spun out of Ligand Pharmaceuticals, OmniAb operates transgenic animal platforms and AI-driven tools that help biopharmaceutical partners discover therapeutic antibodies across oncology, immunology, and infectious disease. Sign up at SpacDesk for complete filing history, sponsor data, and deal analytics on OmniAb and the broader SPAC market.